stoxline Quote Chart Rank Option Currency Glossary
Inhibikase Therapeutics, Inc. (IKT)
0.9242  -0.013 (-1.42%)    12-01 16:00
Open: 0.9
High: 0.95
Volume: 29,694
Pre. Close: 0.9375
Low: 0.87
Market Cap: 6(M)
Technical analysis
2023-12-01 4:20:41 PM
Short term     
Mid term     
Targets 6-month :  1.16 1-year :  1.3
Resists First :  0.99 Second :  1.12
Pivot price 0.92
Supports First :  0.79 Second :  0.66
MAs MA(5) :  0.91 MA(20) :  0.95
MA(100) :  1.61 MA(250) :  2.92
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  44 D(3) :  37.9
RSI RSI(14): 46.6
52-week High :  6.94 Low :  0.79
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ IKT ] has closed below upper band by 44.6%. Bollinger Bands are 79.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 27 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.95 - 0.96 0.96 - 0.96
Low: 0.86 - 0.86 0.86 - 0.87
Close: 0.93 - 0.93 0.93 - 0.94
Company Description

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Headline News

Fri, 01 Dec 2023
Top Penny Stocks for Q4 2023 - Investopedia

Tue, 07 Nov 2023
Inhibikase Therapeutics to Report Second Quarter Financial Results ... - InvestorsObserver

Mon, 16 Oct 2023
Inhibikase Therapeutics Highlights Unblinded Functional Analysis ... - BioSpace

Wed, 04 Oct 2023
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for ... - GlobeNewswire

Thu, 24 Aug 2023
Inhibikase Therapeutics Announces Development of Novel ... - PR Newswire

Thu, 17 Aug 2023
Inhibikase Therapeutics Announces Completion of the 501 ... - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 6 (M)
Held by Insiders 5.27e+006 (%)
Held by Institutions 22.4 (%)
Shares Short 48 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.985e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -5 %
Return on Assets (ttm) 993.3 %
Return on Equity (ttm) -53.9 %
Qtrly Rev. Growth 324070 %
Gross Profit (p.s.) 991.29
Sales Per Share -95.28
EBITDA (p.s.) 0
Qtrly Earnings Growth -4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -18 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.33
Stock Dividends
Dividend 0
Forward Dividend 177890
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android